Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
PASADENA, Calif.--(BUSINESS WIRE)--Nov 18, 2019--
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated Phase 1 clinical data on its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a potential treatment for patients with severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS), and ARO-ANG3 targeting angiopoietin like protein 3 (ANGPTL3) being developed for the treatment of dyslipidemias, such as homozygous familial hypercholesterolemia (HoFH), and metabolic diseases. The data were presented in two late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2019, in Philadelphia.
Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “The data presented at AHA on cardiometabolic candidates ARO-APOC3 and ARO-ANG3 are further validation of the TRiM™ platform and Arrowhead’s ability to consistently develop RNAi therapeutics that achieve deep and durable levels of gene knockdown across a broad range of targets. In particular, the knockdown in APOC3 and ANGPTL3 proteins and the resulting reductions in triglycerides and various lipid parameters strongly support our plan to initiate Phase 3 studies in 2020.”
RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides
Key points presented on the AROAPOC31001 Phase 1/2a clinical study included the following:
RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects
Key points presented on the AROANG1001 Phase 1/2a clinical study included the following:
Copies of the presentations can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005259/en/
CONTACT: Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
firstname.lastname@example.orgInvestors and Media:
LifeSci Advisors, LLC
KEYWORD: CALIFORNIA PENNSYLVANIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENETICS CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL CARDIOLOGY
SOURCE: Arrowhead Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 11/18/2019 09:32 AM/DISC: 11/18/2019 09:32 AM